Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Genotype Prostate Cancer Samples for Cancer Research UK in $7M Deal

NEW YORK, April 11 (GenomeWeb News) - Illumina will genotype prostate cancer samples for Cancer Research UK, the company said today.

 

Under the agreement, valued at almost $7 million, Illumina will provide genotyping services to researchers at Cancer Research UK, a non-profit research organization. Initially, Ilumina will conduct whole-genome genotyping for at least 4,000 prostate patients samples and controls. In a second phase, the company will develop a custom, 12-sample BeadChip that it will use to genotype at least 8,000 samples. Illumina will use its Sentrix BeadChips and Infinium assay for the project.

 

The goal is to identify potential cancer biomarkers, and to analyze chromosomal aberrations.

 

This is the second genotyping service agreement between the two partners in the last six months. In November, Cancer Research UK selected Illumina to provide genotyping services for colorectal cancer.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.